Page last updated: 2024-12-06

propranolol glycol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

propranolol glycol: propranolol metabolite; potent anticonvulsant against strychnine induced convulsions [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37369
CHEMBL ID528080
SCHEMBL ID6483890
MeSH IDM0060827

Synonyms (47)

Synonym
OPREA1_270821
1-(2,3-dihydroxypropoxy)naphthalene
naphthalene, 1-(2,3-dihydroxypropoxy)-
propanolol glycol
1,2-propanediol, 3-(1-naphthyloxy)-
3-(alpha-naphthoxy)-1,2-propanediol
propranolol glycol
NCGC00024825-02
3-naphthalen-1-yloxypropane-1,2-diol
CHEMBL528080
gnf-pf-4919 ,
unii-fu45bo16rf
fu45bo16rf ,
36112-95-5
AKOS017547804
3-(1-naphthyloxy)propane-1,2-diol
SCHEMBL6483890
1-(.alpha.-naphthoxy)-2,3-propylene glycol
3-(.alpha.-naphthoxy)-1,2-propanediol
BYNNMWGWFIGTIC-UHFFFAOYSA-N
3-(1-naphthyloxy)-1,2-propanediol #
1,2-propanediol, 3-(1-naphthalenyloxy)-
2,3-dihydroxy-1-(1-naphthalenoxy)propane
3-(1-naphthalenyloxy)-1,2-propanediol
propranolol hydrochloride impurity a [ep impurity]
propranolol glycol, (+/-)-
3-(.alpha.-naphthoxy)-1,2-propylene glycol
(2rs)-3-(naphthalen-1-yloxy)propane-1,2-diol
sr-01000597456
SR-01000597456-1
3-(1-naphthalenyloxy)-1,2-propanediol, analytical standard
propranolol hydrochloride imp. a (ep); propranolol imp. a (ep); (2rs)-3-(naphthalen-1-yloxy)propane-1,2-diol; diol derivative of propranolol; propranolol hydrochloride impurity a; propranolol impurity a
(2rs)-3-(naphthalen-1-yloxy)propane-1,2-diol (diol derivative)
1,2-dihydroxy-3-(1-naphthoxy)-propane
A899636
F19317
3-(naphthalen-1-yloxy)propane-1,2-diol
mfcd00673941
AS-48153
Q27278206
3-(naphthalen-1-yloxy)propane-1,2- diol
propranololglycol
DTXSID10865804
3-[(naphthalen-1-yl)oxy]propane-1,2-diol
EN300-370926
Z1551645244
PD079034

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" In contrast, the (R)-glycol appeared to act as an irreversible antagonist, producing complex dose-response curves."( Comparative studies with the enantiomers of the glycol metabolite of propranolol and their effects on the cardiac beta-adrenoceptor.
Lyles, GA; Neilson, DG; Ogg, GD; Stevenson, IH, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.11920.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.07 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]